Evolution of the Cognitive Profile and Quality of Life of Adult Patients Suffering From Severe Migraines Under Preventive Treatment
Condition(s) studied
Investigational drug(s) / intervention(s)
Cognitive assessment mapping: Test E-Miles - MoCA - MMSE
Study summary
In chronic migraine, we routinely use innovative treatments such as peri-cranial injections of botulinum toxin type A according to the PREEMPT protocol, or intravenous Eptinezumab, both targeting the Calcitonin Gene-Related Peptide (CGRP). We observe significant improvement in 70-80% of our patients after one year of treatment, corresponding to at least a 30-50% reduction in the number of migraines per month, together with improvements in anxiety and depression comorbidities (HADS), catastrophizing scores (PCS), and the impact of migraines on quality of life (HIT-6).
Our main hypothesis, based on our clinical experience and the literature, is that the cognitive profile of these adult patients-particularly attention and memory, as assessed by a validated self-report questionnaire-improves following treatment with botulinum toxin type A administered according to the PREEMPT protocol or intravenous anti-CGRP antibody infusions (Eptinezumab), alongside improvement in migraine disease activity (number of migraines per month), after one year of treatment.
Eligibility
Primary outcome measure(s)
- E-MILE cognitive profile mapping — Month12
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Hôpitaux Universitaires de Strasbourg | Strasbourg | France |
More University Hospital, Strasbourg, France trials in France
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07691164 on ClinicalTrials.gov ↗ ← All trials in France